際際滷

際際滷Share a Scribd company logo
*Generic Name:
Esomeprazole USP 20 mg
*Indications:
 1. Gastroesophageal Reflux Disease (GERD), Healing
of erosive esophagitis, Symptomatic GERD
 2. Duodenal ulcer, Gastric ulcer
 3. Zollinger-Ellison syndrome
 4. Risk Reduction of NSAID- associated gastric ulcer
 5. H. pylori eradication (as Triple therapy)
*Market Share:
Rank Brand Name Manufacturer Total Sales (Tk.) Market Share Growth
ESOMEPRAZOLE 4,407,954,375 34.06 30.42
1 MAXPRO Renata 1,072,352,784 24.33 25.27
2 SERGEL Healthcare 716,136,535 16.25 33.84
3 EXIUM Radiant 348,002,038 7.89 31.72
4 ESONIX Incepta 309,029,835 7.01 32.33
5 NEXUM Square 305,078,604 6.92 25.08
42 Asozit WHPL 2,815,539 0.06 ..........%
*Target Doctors:
 GP/RMP/DCC
 Medicine Specialist
 Dentists
 Orthopedic Surgeons
 Rheumatologists
 All types of Physicians
Number
of MPO
for this
Product
Numbe
r of
Doctor
/ MPO
for this
product
No of
Visit
Doc/
/week
Total
No of
visit of
a MPO/
week
Total
No of
visit of
a MPO /
month
No of
Rx /
Doc /
week
No of
Rx
/Doc/
Month
No of
Rx /
MPO /
Month
265 10 3 30 120 9 36 360
*Prescription Objective:
:
*Key Presentation
 Esomeprazole Suppress gastric acid secretion by specific
inhibition of the H+/K+ ATPase in the parietal cells of the
stomach.
 Esomeprazole blocks the final step in acid production, thus
reducing gastric acidity.
 A recent clinical study showed that, statistically Esomeprazole
compared with the other PPIs significantly increase in the
probability of relieve of Gastroesophageal Reflux Disease (GERD
) symptoms at the end of 4 weeks trial.
 Manufactured in a ISO certified World Class CGMP monitored
"State of the Art Plant".
 Highly sophisticated technologies are being used.
 DMF grade pellets are used.
 Ensures excellent Peptic Ulcer diseases efficacy.
*Visiting Plan
Visit 1st Week 2nd Week 3rd Week 4th Week
1st Visit Pen + Showcard Pen+ Showcard Pen + Showcard Pen+Showcard
2nd Visit
Gen. Sam.+
Showcard
Gen. Sample +
Showcard
Gen. Sample+
Showcard
Gen.
Sample+Showcard
3rd Visit Gift+ Showcard Sample+ Showcard Gift+ Showcard Sample+Showcard
Detailing Tips
爨伍爨爨鉦Π,
爨爨伍 爨伍爨鉦Σ爨鉦Ξ爭 爨爨迦鉦爨爭爨爛
 爨爨爨鉦Ζ爭爨 Product Prescribe 爨爨萎鉦Π 爨爨爭爨 爨踶爨 The White Horse-爨爨 Patronize 爨爨萎鉦Π
爨爨爭爨 爨爨爭爨 爨оΘ爭爨爨爨鉦爛
 爨爨爨爨爭 爨項爨爨萎爨 爨爨萎爨 爨爨鉦Ζ爨爭 PPI Market-爨踶 Brand Leader 爨爨鉦Π爨, 爨萎爨鉦Ζ爭爨 Brand 爨爭爨爨迦
Prescribe 爨爨萎Ζ爭爨爭爛 爨爨爨鉦Ζ爭爨 Asozit Brand-爨爨 爨 Already Market 爨 available
爨爨爭爛
 Sir, Asozit ensures desired quality which you are expecting from a quality
Esomeprazole. (sample)
 爨伍爨鉦Ξ爭爨爭爨萎Θ爨萎爨 爨伍爨爨爭爨 爨爨爨爨劇Θ爭爨鉦Σ爨爭爨爭爨 爨爨迦鉦Λ爨 爨爭爨爨 爨爭爨爨 爨爨爨爭, 爨伍爨爨 G.I Product 爨踶
爨爭爨爭 Esomperazole Generics-爨踶 Superiority 爨爨爨爭爨 爨爨爨爭 爛 爨爨爨爭爨鉦Π 爨爨爭爨逗爨爭爨萎
爨爨爭爭爨伍爨爭爨о鉦Θ爭 爨踶爨 爨伍爨鉦Θ爨爨む 爨爨爨迦Θ爨оΠ 爨爨爭爨 爨伍爨爨鉦Π 爨爨爨鉦Ζ爭爨 Asozit 爨踶 (PPM)爛
 爨爨爨鉦Ζ爭爨 爨爨鉦Ζ爭 爨伍爨鉦Μ爨む爭爨劇Θ爨爭爨爨爨鉦Ζ爨 爭爨鉦爨鉦Π 爨爨爭爨 爨爨爭爨 爨оΘ爭爨爨爨鉦爛 爨伍爨爨鉦Π, 爨爨爨 爨伍爨 爨伍爨爭爨
Asozit 爨爨爨爭 爨爨爨萎Ζ爭 爨爭爨爛 爨爭爨 爨爨萎Θ爭 爨爭爨萎Θ爨萎爨爭爨爭 爨爨爨爨爭 Asozit 爨踶 at least 爭爭爨(爭)爨爨
爨爨爨 Prescription Support 爨爭爨爭 爨爨爨鉦Ζ爭爨 Product 爨踶 Branding-爨爨 Mobilize
爨爨萎Ζ爨爨爭爛 (Gift)
爨爨迦爨迦鉦 爨項鉦Ζ爨爨爛
Thanks Everyone

More Related Content

Asozit

  • 2. *Indications: 1. Gastroesophageal Reflux Disease (GERD), Healing of erosive esophagitis, Symptomatic GERD 2. Duodenal ulcer, Gastric ulcer 3. Zollinger-Ellison syndrome 4. Risk Reduction of NSAID- associated gastric ulcer 5. H. pylori eradication (as Triple therapy)
  • 3. *Market Share: Rank Brand Name Manufacturer Total Sales (Tk.) Market Share Growth ESOMEPRAZOLE 4,407,954,375 34.06 30.42 1 MAXPRO Renata 1,072,352,784 24.33 25.27 2 SERGEL Healthcare 716,136,535 16.25 33.84 3 EXIUM Radiant 348,002,038 7.89 31.72 4 ESONIX Incepta 309,029,835 7.01 32.33 5 NEXUM Square 305,078,604 6.92 25.08 42 Asozit WHPL 2,815,539 0.06 ..........%
  • 4. *Target Doctors: GP/RMP/DCC Medicine Specialist Dentists Orthopedic Surgeons Rheumatologists All types of Physicians
  • 5. Number of MPO for this Product Numbe r of Doctor / MPO for this product No of Visit Doc/ /week Total No of visit of a MPO/ week Total No of visit of a MPO / month No of Rx / Doc / week No of Rx /Doc/ Month No of Rx / MPO / Month 265 10 3 30 120 9 36 360 *Prescription Objective:
  • 6. : *Key Presentation Esomeprazole Suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase in the parietal cells of the stomach. Esomeprazole blocks the final step in acid production, thus reducing gastric acidity. A recent clinical study showed that, statistically Esomeprazole compared with the other PPIs significantly increase in the probability of relieve of Gastroesophageal Reflux Disease (GERD ) symptoms at the end of 4 weeks trial. Manufactured in a ISO certified World Class CGMP monitored "State of the Art Plant". Highly sophisticated technologies are being used. DMF grade pellets are used. Ensures excellent Peptic Ulcer diseases efficacy.
  • 7. *Visiting Plan Visit 1st Week 2nd Week 3rd Week 4th Week 1st Visit Pen + Showcard Pen+ Showcard Pen + Showcard Pen+Showcard 2nd Visit Gen. Sam.+ Showcard Gen. Sample + Showcard Gen. Sample+ Showcard Gen. Sample+Showcard 3rd Visit Gift+ Showcard Sample+ Showcard Gift+ Showcard Sample+Showcard
  • 8. Detailing Tips 爨伍爨爨鉦Π, 爨爨伍 爨伍爨鉦Σ爨鉦Ξ爭 爨爨迦鉦爨爭爨爛 爨爨爨鉦Ζ爭爨 Product Prescribe 爨爨萎鉦Π 爨爨爭爨 爨踶爨 The White Horse-爨爨 Patronize 爨爨萎鉦Π 爨爨爭爨 爨爨爭爨 爨оΘ爭爨爨爨鉦爛 爨爨爨爨爭 爨項爨爨萎爨 爨爨萎爨 爨爨鉦Ζ爨爭 PPI Market-爨踶 Brand Leader 爨爨鉦Π爨, 爨萎爨鉦Ζ爭爨 Brand 爨爭爨爨迦 Prescribe 爨爨萎Ζ爭爨爭爛 爨爨爨鉦Ζ爭爨 Asozit Brand-爨爨 爨 Already Market 爨 available 爨爨爭爛 Sir, Asozit ensures desired quality which you are expecting from a quality Esomeprazole. (sample) 爨伍爨鉦Ξ爭爨爭爨萎Θ爨萎爨 爨伍爨爨爭爨 爨爨爨爨劇Θ爭爨鉦Σ爨爭爨爭爨 爨爨迦鉦Λ爨 爨爭爨爨 爨爭爨爨 爨爨爨爭, 爨伍爨爨 G.I Product 爨踶 爨爭爨爭 Esomperazole Generics-爨踶 Superiority 爨爨爨爭爨 爨爨爨爭 爛 爨爨爨爭爨鉦Π 爨爨爭爨逗爨爭爨萎 爨爨爭爭爨伍爨爭爨о鉦Θ爭 爨踶爨 爨伍爨鉦Θ爨爨む 爨爨爨迦Θ爨оΠ 爨爨爭爨 爨伍爨爨鉦Π 爨爨爨鉦Ζ爭爨 Asozit 爨踶 (PPM)爛 爨爨爨鉦Ζ爭爨 爨爨鉦Ζ爭 爨伍爨鉦Μ爨む爭爨劇Θ爨爭爨爨爨鉦Ζ爨 爭爨鉦爨鉦Π 爨爨爭爨 爨爨爭爨 爨оΘ爭爨爨爨鉦爛 爨伍爨爨鉦Π, 爨爨爨 爨伍爨 爨伍爨爭爨 Asozit 爨爨爨爭 爨爨爨萎Ζ爭 爨爭爨爛 爨爭爨 爨爨萎Θ爭 爨爭爨萎Θ爨萎爨爭爨爭 爨爨爨爨爭 Asozit 爨踶 at least 爭爭爨(爭)爨爨 爨爨爨 Prescription Support 爨爭爨爭 爨爨爨鉦Ζ爭爨 Product 爨踶 Branding-爨爨 Mobilize 爨爨萎Ζ爨爨爭爛 (Gift) 爨爨迦爨迦鉦 爨項鉦Ζ爨爨爛